相关实验视频
Updated: Jun 24, 2025

06:08
A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
23.4K
鉴定硫烯胺素作为新型选择性阿尔多氨酸合成酶 (CYP11B2) 抑制剂
Masaki Meguro1, Satoru Miyauchi2, Yukiko Kanao-Arisumi3
1Shinagawa R&D Center, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan.
Bioorganic & medicinal chemistry
|June 8, 2024
概括
一种新型的强效阿尔多氨酸合成酶抑制剂,化合物2,有效降低阿尔多氨酸水平. 它对人类CYP11B2具有很高的选择性,提供了一个有前途的治疗标.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
背景情况:
- 阿尔多氨酸合成酶 (CYP11B2) 是雷宁- ангиотензин-阿尔多氨酸系统中的一个关键酶.
- 抑制CYP11B2为阿尔多激素过量障碍提供了潜在的治疗策略.
- 开发选择性CYP11B2抑制剂是具有挑战性的,因为其与CYP11B1.1的序列同质性.
研究的目的:
- 确定和描述人类阿尔多氨酸合成酶 (CYP11B2) 的新型强效抑制剂.
- 为了评估一种新兴抑制剂的体外和体内疗效和选择性,化合物2.
- 评估化合物2作为治疗阿尔多激素过量相关疾病的治疗剂的潜力.
主要方法:
- 在体外酶分析以确定对人类CYP11B2和CYP11B1.1的抑制功效.
- 在体内研究中,使用治疗过罗塞米德的Cynomolgus子模型来评估降低阿尔多素的效果.
- 试验室内选择性测定用于比较CYP11B2和CYP11B1.1之间的抑制.
主要成果:
- 化合物2被确定为一种人类CYP11B2的新型,强有力的抑制剂,其活性在纳米分子范围内.
- 化合物2在临床前的动物模型中表现出显著的阿尔多素降低作用.
- 化合物2在体外对人类CYP11B1比人类CYP11B2具有很高的选择性 (>80倍).
结论:
- 化合物2是一种新且强大的阿尔多氨酸合成酶抑制剂.
- 化合物2对CYP11B2的高选择性表明它具有有利的治疗特征.
- 化合物2需要进一步研究用于治疗阿尔多素依赖性疾病.
相关概念视频
Oral Hypoglycemic Agents: Sulfonylureas
205
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
205
Antihypertensive Drugs: Potassium-Sparing Diuretics
512
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
512
Antihypertensive Drugs: Thiazide-Class Diuretics
598
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
598
Antihypertensive Drugs: Direct Renin Inhibitors
585
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
585
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
617
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
617

